Entera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference

BOSTON and JERUSALEM, Nov. 02, 2020 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will host a virtual presentation at the H.C. Wainwright Annual Israel Conference on Thursday, November 12, 2020 at 8:00 a.m. ET.

To access a live webcast of the fireside chat on the "Investor Relations" page of Entera's website, please click here. A replay of the webcast will be archived on Entera's website for approximately 45 days following the presentation.

About Entera Bio

Entera is a leader in the development of orally delivered macromolecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit www.enterabio.com.

EB5 Capital Achieves $100+ Million Repayment Milestone

WASHINGTON, Nov. 02, 2020 (GLOBE NEWSWIRE) — Today EB5 Capital announced it has surpassed $100 million in repayments to its EB–5 investors. The United States Citizenship and Immigration Services' (USCIS) EB–5 Program permits foreign nationals and their immediate family to apply for US residency through an investment in a job–creating real estate project. Repayments to investors represent the successful investing and return of capital to clients.

"Since our work began in 2008, we've proven our ability to invest our clients' money in sound, job–creating commercial real estate projects that fully meet the requirements set out by USCIS," said Brian Ostar, EB5 Capital's President. "Throughout this year, asset management has been our top–priority, and completing the full EB–5 cycle across a dozen projects is extremely rewarding to us, the clients we've repaid, and clients in earlier stages of their immigration process."

EB5 Capital has increased the frequency of its communication with developer–partners and investors. Despite the changes brought on by the COVID–19 pandemic, the firm remains focused on operating efficiencies and the pursuit of sound EB–5 investment opportunities for those considering moving to the US through an EB–5 investment.

"The pandemic has caused quite a bit of uncertainty for our firm and clients this year," said Juline Kaleyias, EB5 Capital's Director of Business Development. "Though, our team is still very much committed, working harder and more efficiently than ever. We are delighted to deliver this good news."

About EB5 Capital

EB5 Capital is a leader in the EB–5 immigrant investor industry, raising over $750 million in foreign capital from investors in more than 65 countries for investment in job–creating real estate projects across the United States. EB5 Capital owns and operates five USCIS–authorized Regional Centers that serve 14 states and the District of Columbia. With a portfolio of 28 projects, EB5 Capital maintains a 100% project approval rate from the USCIS. For more information, visit http://www.eb5capital.com.

Contact:
Ben Carter
(202) 652–2437
media@eb5capital.com

Economic Trends and What’s Important in Life

By Anis Chowdhury and Jomo Kwame Sundaram
SYDNEY and KUALA LUMPUR, Nov 2 2020 - US third quarter GDP numbers released two weeks ago delighted stock markets and President Trump. Output had picked up by 7.4%, annualised as 33.1%, the [...] Read more »